OHR Pharmaceutical, Inc., a clinical-stage pharmaceutical company, focuses on the development of novel therapies for the treatment of ophthalmic diseases. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating Squalamine in combination with Lucentis injections, which completed Phase II clinical trials for the treatment of retinal diseases, including wet form of age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy. It is also developing a sustained release ocular drug delivery platform technology. OHR Pharmaceutical, Inc. is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-682-8452
Debt
Current Ratio5.54
Quick Ratio5.54
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book0.63
Profitability
Net Income$-13,230,000.00
Net MarginsN/A
Return on Assets-75.77%
Miscellaneous
Employees3
OptionableOptionable
OHR Pharmaceutical (NASDAQ:OHRP) Frequently Asked Questions
What is OHR Pharmaceutical's stock symbol?
OHR Pharmaceutical trades on the NASDAQ under the ticker symbol "OHRP."
How were OHR Pharmaceutical's earnings last quarter?
When is OHR Pharmaceutical's next earnings date?
Has OHR Pharmaceutical been receiving favorable news coverage?
Press coverage about OHRP stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OHR Pharmaceutical earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of OHR Pharmaceutical's key competitors?
Some companies that are related to OHR Pharmaceutical include Oncomed Pharmaceuticals (OMED), Eyenovia (EYEN), IMMURON LTD/S (IMRN), Agile Therapeutics (AGRX), Trillium Therapeutics (TRIL), Sunesis Pharmaceuticals (SNSS), Q BioMed (QBIO), Provectus Biopharmaceuticals (PVCT), Ceapro (CRPOF), OvaScience (OVAS), ESSA Pharma (EPIX), Acerus Pharmaceuticals (TRLPF), Genprex (GNPX), Sernova (SEOVF) and GTX (GTXI).
Who are OHR Pharmaceutical's key executives?
OHR Pharmaceutical's management team includes the folowing people:
- Dr. Jason Scott Slakter, CEO, Pres & Director (Age 61)
- Mr. Samuel Backenroth, CFO, VP of Bus. Devel. & Sec. (Age 35)
- Dr. Glenn L. Stoller M.D., Chief Scientific Officer (Age 55)
- Dr. Marlene Modi, Head of Preclinical & Regulatory Affairs
How do I buy shares of OHR Pharmaceutical?
Shares of OHRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OHR Pharmaceutical's stock price today?
One share of OHRP stock can currently be purchased for approximately $0.12.
How big of a company is OHR Pharmaceutical?
OHR Pharmaceutical has a market capitalization of $7.34 million. OHR Pharmaceutical employs 3 workers across the globe.
What is OHR Pharmaceutical's official website?
How can I contact OHR Pharmaceutical?
OHR Pharmaceutical's mailing address is 800 THIRD AVENUE 11TH FLOOR, NEW YORK NY, 10022. The biotechnology company can be reached via phone at 212-682-8452 or via email at [email protected]
MarketBeat Community Rating for OHR Pharmaceutical (NASDAQ OHRP)
MarketBeat's community ratings are surveys of what our community members think about OHR Pharmaceutical and other stocks. Vote "Outperform" if you believe OHRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OHRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
